Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs

Orlynvah (Iterum Therapeutics), an oral fixed-dose combination of the thiopenem antibacterial prodrug sulopenem etzadroxil and the renal tubular transport inhibitor probenecid, has been approved by the FDA for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in women who have limited or no alternative oral antibacterial treatment options. It is the first oral penem-containing product to be approved in the US.